{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:52:15Z","timestamp":1780066335221,"version":"3.54.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,4,28]],"date-time":"2013-04-28T00:00:00Z","timestamp":1367107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s11882-013-0345-0","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T20:24:30Z","timestamp":1367439870000},"page":"308-314","source":"Crossref","is-referenced-by-count":63,"title":["Use of Cyclosporine A and Tacrolimus in Treatment of Vernal Keratoconjunctivitis"],"prefix":"10.1007","volume":"13","author":[{"given":"Pakit","family":"Vichyanond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panida","family":"Kosrirukvongs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,28]]},"reference":[{"key":"345_CR1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","volume":"89","author":"N Pucci","year":"2002","unstructured":"Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89:298\u2013303.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"345_CR2","first-page":"25","volume":"21","author":"P Kosrirukvongs","year":"2003","unstructured":"Kosrirukvongs P, Vichyanond P, Wongsawad W. Vernal keratoconjunctivitis in Thailand. Asian Pac J Allergy Immunol. 2003;21:25\u201330.","journal-title":"Asian Pac J Allergy Immunol."},{"key":"345_CR3","doi-asserted-by":"crossref","unstructured":"\u2022 Lambiase A, Minchiotti S, Leonardi A, et al. Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population. Ophthalmic Epidemiol. 2009;16:38\u201341. A recent large study examining epidemiology of VKC from Italy.","DOI":"10.1080\/09286580802573177"},{"key":"345_CR4","doi-asserted-by":"crossref","unstructured":"\u2022 Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002;21:319\u201339. A must to read for all interested in basic and clinical research of VKC.","DOI":"10.1016\/S1350-9462(02)00006-X"},{"key":"345_CR5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bjo.79.5.482","volume":"79","author":"A Leonardi","year":"1995","unstructured":"Leonardi A, Abatangelo G, Cortivo R, Secchi AG. Collagen types I and III in giant papillae of vernal keratoconjunctivitis. Br J Ophthalmol. 1995;79:482\u20135.","journal-title":"Br J Ophthalmol"},{"key":"345_CR6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2222.2006.02499.x","volume":"36","author":"A Leonardi","year":"2006","unstructured":"Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy. 2006;36:777\u201384.","journal-title":"Clin Exp Allergy."},{"key":"345_CR7","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1398-9995.2008.01858.x","volume":"64","author":"A Leonardi","year":"2009","unstructured":"Leonardi A, Sathe S, Bortolotti M, et al. Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients. Allergy. 2009;64:710\u20137.","journal-title":"Allergy"},{"key":"345_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/sj.eye.6701811","volume":"20","author":"AM Abu El-Asrar","year":"2006","unstructured":"Abu El-Asrar AM, Al-Mansouri S, Tabbara KF, et al. Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis. Eye (Lond). 2006;20:71\u20139.","journal-title":"Eye (Lond)."},{"key":"345_CR9","first-page":"4175","volume":"41","author":"A Leonardi","year":"2000","unstructured":"Leonardi A, Brun P, Tavolato M, et al. Growth factors and collagen distribution in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2000;41:4175\u201381.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"345_CR10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1076\/ceyr.26.5.319.15437","volume":"26","author":"SD Trocme","year":"2003","unstructured":"Trocme SD, Leiferman KM, George T, et al. Neutrophil and eosinophil participation in atopic and vernal keratoconjunctivitis. Curr Eye Res. 2003;26:319\u201325.","journal-title":"Curr Eye Res"},{"key":"345_CR11","first-page":"394","volume":"13","author":"A Iqbal","year":"2003","unstructured":"Iqbal A, Jan S, Babar TF, Khan MD. Corneal complications of vernal catarrh. J Coll Physicians Surg Pak. 2003;13:394\u20137.","journal-title":"J Coll Physicians Surg Pak"},{"key":"345_CR12","doi-asserted-by":"crossref","unstructured":"\u2022 Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000;11:478\u201383. A complete comprehensive review of ocular complications of corticosteroids.","DOI":"10.1097\/00055735-200012000-00016"},{"key":"345_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 Borazan M, Karalezli A, Akova YA, et al. Efficacy of olopatadine HCI 0.1\u00a0%, ketotifen fumarate 0.025\u00a0%, epinastine HCI 0.05\u00a0%, emedastine 0.05\u00a0% and fluorometholone acetate 0.1\u00a0% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol. 2009;87:549\u201354. Comparison of various topical treatments for ocular allergy.","DOI":"10.1111\/j.1755-3768.2008.01265.x"},{"key":"345_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/112067210101100203","volume":"11","author":"P Verin","year":"2001","unstructured":"Verin P, Allewaert R, Joyaux JC, et al. Comparison of lodoxamide 0.1\u00a0% ophthalmic solution and levocabastine 0.05\u00a0% ophthalmic suspension in vernal keratoconjunctivitis. Eur J Ophthalmol. 2001;11:120\u20135.","journal-title":"Eur J Ophthalmol"},{"key":"345_CR15","first-page":"239","volume":"61","author":"D Das","year":"2011","unstructured":"Das D, Khan M, Gul A, Alam R. Safety and efficacy of lodoxamide in vernal keratoconjunctivitis. J Pak Med Assoc. 2011;61:239\u201341.","journal-title":"J Pak Med Assoc"},{"key":"345_CR16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0161-6420(88)33201-X","volume":"95","author":"CS Foster","year":"1988","unstructured":"Foster CS. Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology. 1988;95:194\u2013201.","journal-title":"Ophthalmology"},{"key":"345_CR17","doi-asserted-by":"crossref","unstructured":"\u2022 Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol. 2007;91:1656\u201361. A comprehensive summary and meta-analysis of efficacy of various topical treatment regimen for VKC.","DOI":"10.1136\/bjo.2007.122044"},{"key":"345_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2133.2001.03948.x","volume":"144","author":"AM Farrell","year":"2001","unstructured":"Farrell AM, Antrobus P, Simpson D, et al. A rapid flow cytometric assay to detect CD4+ and CD8+ T-helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy. Br J Dermatol. 2001;144:24\u201333.","journal-title":"Br J Dermatol"},{"key":"345_CR19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/sj.ki.5002255","volume":"72","author":"C Libetta","year":"2007","unstructured":"Libetta C, Sepe V, Zucchi M, et al. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. Kidney Int. 2007;72:114\u201320.","journal-title":"Kidney Int"},{"key":"345_CR20","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/bjo.2005.070888","volume":"89","author":"S Tatlipinar","year":"2005","unstructured":"Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol. 2005;89:1363\u20137.","journal-title":"Br J Ophthalmol"},{"key":"345_CR21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0002-9394(86)90819-6","volume":"101","author":"D BenEzra","year":"1986","unstructured":"BenEzra D, Pe\u2019er J, Brodsky M, Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol. 1986;101:278\u201382.","journal-title":"Am J Ophthalmol"},{"key":"345_CR22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9394(14)77061-8","volume":"110","author":"AG Secchi","year":"1990","unstructured":"Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol. 1990;110:641\u20135.","journal-title":"Am J Ophthalmol"},{"key":"345_CR23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3129\/i06-061","volume":"41","author":"A Kilic","year":"2006","unstructured":"Kilic A, Gurler B. Topical 2\u00a0% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006;41:693\u20138.","journal-title":"Can J Ophthalmol"},{"key":"345_CR24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1399-3038.2006.00427.x","volume":"17","author":"L Spadavecchia","year":"2006","unstructured":"Spadavecchia L, Fanelli P, Tesse R, et al. Efficacy of 1.25\u00a0% and 1\u00a0% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol. 2006;17:527\u201332.","journal-title":"Pediatr Allergy Immunol."},{"key":"345_CR25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1023\/A:1013671819604","volume":"19","author":"M Kuwano","year":"2002","unstructured":"Kuwano M, Ibuki H, Morikawa N, et al. Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm Res. 2002;19:108\u201311.","journal-title":"Pharm Res"},{"key":"345_CR26","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1\u00a0% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:365\u201372. Report of an efficacy of a new aqueous base CsA solution in various forms of severe conjunctivitis including VKC.","DOI":"10.1089\/jop.2008.0103"},{"key":"345_CR27","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lambiase A, Leonardi A, Sacchetti M, et al. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol. 2011;128:896\u20137 e9. Newer concept of treatment of VKC using long-term treatment with topical CsA.","DOI":"10.1016\/j.jaci.2011.07.004"},{"key":"345_CR28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/bjo.2005.082461","volume":"90","author":"M Daniell","year":"2006","unstructured":"Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90:461\u20134.","journal-title":"Br J Ophthalmol"},{"key":"345_CR29","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1073\/pnas.92.24.11205","volume":"92","author":"KT Shaw","year":"1995","unstructured":"Shaw KT, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A. 1995;92:11205\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"345_CR30","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.4049\/jimmunol.146.7.2374","volume":"146","author":"A Paulis de","year":"1991","unstructured":"de Paulis A, Cirillo R, Ciccarelli A, et al. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI\u2009+\u2009cells. J Immunol. 1991;146:2374\u201381.","journal-title":"J Immunol"},{"key":"345_CR31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199709183371203","volume":"337","author":"T Ruzicka","year":"1997","unstructured":"Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997;337:816\u201321.","journal-title":"N Engl J Med"},{"key":"345_CR32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0091-6749(98)70281-7","volume":"102","author":"M Boguniewicz","year":"1998","unstructured":"Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102:637\u201344.","journal-title":"J Allergy Clin Immunol."},{"key":"345_CR33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1468-3083.2012.04635.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"345_CR34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaci.2012.12.672","volume":"131","author":"L Schneider","year":"2013","unstructured":"Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131:295\u20139.e27.","journal-title":"J Allergy Clin Immunol"},{"key":"345_CR35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-001-0424-0","volume":"240","author":"K Nishino","year":"2002","unstructured":"Nishino K, Fukushima A, Okamoto S, et al. Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506. Graefes Arch Clin Exp Ophthalmol. 2002;240:137\u201343.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"345_CR36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2003.10.065","volume":"113","author":"P Vichyanond","year":"2004","unstructured":"Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et al. Vernal keratoconjunctivitis: Result of a novel therapy with 0.1\u00a0% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol. 2004;113:355\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"345_CR37","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ico.0000214208.14576.1a","volume":"25","author":"AC Cheng","year":"2006","unstructured":"Cheng AC, Yuen K, Chan W. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea. 2006;25:634. author reply.","journal-title":"Cornea"},{"key":"345_CR38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.ico.0000151507.49565.6e","volume":"24","author":"MA Joseph","year":"2005","unstructured":"Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea. 2005;24:417\u201320.","journal-title":"Cornea"},{"key":"345_CR39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-0420.2006.00699.x","volume":"84","author":"HM Virtanen","year":"2006","unstructured":"Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03\u00a0% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand. 2006;84:693\u20135.","journal-title":"Acta Ophthalmol Scand"},{"key":"345_CR40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICO.0b013e3181d83875","volume":"30","author":"DP Garcia","year":"2011","unstructured":"Garcia DP, Alperte JI, Cristobal JA, et al. Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature. Cornea. 2011;30:462\u20135.","journal-title":"Cornea"},{"key":"345_CR41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ICO.0b013e318159afbb","volume":"27","author":"GD Kymionis","year":"2008","unstructured":"Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03\u00a0% in the eye for treatment of giant papillary conjunctivitis. Cornea. 2008;27:228\u20139.","journal-title":"Cornea"},{"key":"345_CR42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","volume":"33","author":"L Attas-Fox","year":"2008","unstructured":"Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03\u00a0% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res. 2008;33:545\u20139.","journal-title":"Curr Eye Res"},{"key":"345_CR43","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/eye.2011.75","volume":"25","author":"A Kheirkhah","year":"2011","unstructured":"Kheirkhah A, Zavareh MK, Farzbod F, et al. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond). 2011;25:872\u201380.","journal-title":"Eye (Lond)"},{"key":"345_CR44","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.jaci.2006.11.536","volume":"119","author":"P Pacharn","year":"2007","unstructured":"Pacharn P, Visitsunthorn N, Jirapongsananuruk O, Vichyanond P. Vernal Keratoconjunctivitis (vkc) Treated With 0.1\u00a0% Fk-506 Ophthalmic Ointment: Result Of A Three Years Follow-up. J Allergy Clin Immunol. 2007;119:S153.","journal-title":"J Allergy Clin Immunol"},{"key":"345_CR45","doi-asserted-by":"crossref","unstructured":"\u2022 Tam PM, Young AL, Cheng LL, Lam PT. Topical tacrolimus 0.03\u00a0% monotherapy for vernal keratoconjunctivitis\u2013case series. Br J Ophthalmol. 2010;94:1405\u20136. An off-label use of dermatologic preparation of FK-506 in VKC treatment.","DOI":"10.1136\/bjo.2009.172387"},{"key":"345_CR46","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1\u00a0% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2010;26:165\u201374. Efficacy of a new FK-506 suspension in AKC and VKC from Japan.","DOI":"10.1089\/jop.2009.0087"},{"key":"345_CR47","unstructured":"\u2022\u2022 Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, et al. A double-masked comparison of 0.1\u00a0% tacrolimus ointment and 2\u00a0% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol. 2012;30:177\u201384. The first comparative trial between topical CsA and FK-506 in VKC."},{"key":"345_CR48","doi-asserted-by":"crossref","unstructured":"\u2022 Zhai J, Gu J, Yuan J, Chen J. Tacrolimus in the treatment of ocular diseases. BioDrugs. 2011;25:89\u2013103. Review of FK-506 as topical treatment for various ocular diseases.","DOI":"10.2165\/11587010-000000000-00000"},{"key":"345_CR49","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1600-0420.2005.00622.x","volume":"84","author":"A Leonardi","year":"2006","unstructured":"Leonardi A, Busca F, Motterle L, et al. Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmol Scand. 2006;84:406\u201310.","journal-title":"Acta Ophthalmol Scand"},{"key":"345_CR50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjophthalmol-2011-300415","volume":"96","author":"S Smedt De","year":"2012","unstructured":"De Smedt S, Nkurikiye J, Fonteyne Y, et al. Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial. Br J Ophthalmol. 2012;96:323\u20138.","journal-title":"Br J Ophthalmol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-013-0345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-013-0345-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-013-0345-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T11:40:00Z","timestamp":1688211600000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-013-0345-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,28]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1007\/s11882-013-0345-0","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,28]]}}}